Answers are grounded in this paper and cite their sources.
Extracellular vesicles (EVs) are lipid bilayer-delimited particles released by cells, carrying molecular information that reflects parental cellular and microenvironmental states, making them increasingly important targets for liquid biopsy. However, EV-based diagnostics are constrained by heterogeneity in EV biogenesis, cellular origin, cargo distribution, and vesicle subtype. Many recurrent EV biomarkers, including commonly reported proteins and RNAs, show limited disease specificity, as similar molecular alterations may occur across cancers, inflammatory conditions, and tissue injury processes. These features highlight the difficulty of extracting discriminative and clinically interpretable information from overlapping biomarker signals while maintaining analytical sensitivity. EV multi-marker analysis converts recurrent biomarker signals into combinatorial molecular signatures, enabling more specific identification of disease-associated EV subpopulations and supporting diagnosis, patient stratification, therapeutic monitoring, and prognostic assessment. This review provides a conceptual and technical framework for advancing EV analysis from single-biomarker detection to integrated molecular decoding. This review first discusses the biological basis and molecular information dimensions of EV multi-marker recognition, including surface proteins, intravesicular nucleic acids, lipid and membrane features, and emerging layers such as glycosylation-related markers and metabolic molecules. Then, key technologies enabling multidimensional EV readout are summarized, focusing on multiplexed protein and nucleic acid detection, protein-RNA co-analysis, membrane-feature-based sensing, single-EV multi-marker profiling, and emerging information-dimensional analysis. Finally, the current status of clinical translation and major challenges are discussed, including biomarker panel design, disease-relevant EV enrichment, standardization, artificial intelligence-assisted data interpretation, and clinical accessibility. This review aims to guide the development of clinically interpretable and actionable EV signatures for precision liquid biopsy.
No takes yet. Share an insight, caveat, or question.
Ma et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: